<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38931912</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Novel Nasal Mucoadhesive Nanoformulations Containing Lipid-Soluble EGCG for Long COVID Treatment.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">791</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16060791</ELocationID><Abstract><AbstractText Label="UNLABELLED">Following recovery from the acute infection stage of the SARS-CoV-2 virus (COVID-19), survivors can experience a wide range of persistent Post-Acute Sequelae of COVID-19 (PASC), also referred to as long COVID. According to the US National Research Action Plan on Long COVID 2022, up to 23.7 million Americans suffer from long COVID, and approximately one million workers may be out of the workforce each day due to these symptoms, leading to a USD 50 billion annual loss of salary. Neurological symptoms associated with long COVID result from persistent infection with SARS-CoV-2 in the nasal neuroepithelial cells, leading to inflammation in the central nervous system (CNS). As of today, there is no evidence that vaccines or medications can clear the persistent viral infection in olfactory mucosa. Recently published clinical data demonstrate that only 5% of long COVID anosmia patients have fully recovered during the past 2 years, and 10.4% of COVID patients are still symptomatic 18 months post-infection. Our group demonstrated that epigallocatechin-3-gallate-monopalmitate (EC16m) nanoformulations possess strong antiviral activity against human coronavirus, suggesting that this green-tea-derived compound in nanoparticle formulations could be developed as an intranasally delivered new drug targeting the persistent SARS-CoV-2 infection, as well as inflammation and oxidative stress in the CNS, leading to restoration of neurologic functions. The objective of the current study was to evaluate the mucociliary safety of the EC16m nasal nanoformulations and their efficacy against human coronavirus.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nanoparticle size and Zeta potential were measured using the ZetaView Nanoparticle Tracking Analysis system; mucociliary safety was determined using the MucilAir human nasal model; contact antiviral activity and post-infection inhibition against the OC43 viral strain were assessed by the TCID50 assay for cytopathic effect on MRC-5 cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The saline-based EC16 mucoadhesive nanoformulations containing 0.005 to 0.02% <i>w</i>/<i>v</i> EC16m have no significant difference compared to saline (0.9% NaCl) with respect to tissue integrity, cytotoxicity, and cilia beat frequency. A 5 min contact resulted in 99.9% inactivation of &#x3b2;-coronavirus OC43. OC43 viral replication was inhibited by &gt;90% after infected MRC-5 cells were treated with the formulations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The saline-based novel EC16m mucoadhesive nasal nanoformulations rapidly inactivated human coronavirus with mucociliary safety properties comparable to saline, a solution widely used for nasal applications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Nicolette</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Oral Biology &amp; Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Camellix Research Laboratory, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovett</LastName><ForeName>Garrison</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oral Biology &amp; Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yutao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2870-4504</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biology &amp; Anatomy, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cellular Biology &amp; Anatomy, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jingwen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3146-3812</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biology &amp; Anatomy, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hangzhou Shanju Biotech Co., Ltd., Hangzhou 310030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiaocui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hangzhou Shanju Biotech Co., Ltd., Hangzhou 310030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oral Biology &amp; Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Camellix Research Laboratory, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R41DC020678-01</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EC16</Keyword><Keyword MajorTopicYN="N">EGCG-palmitate</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">nanoformulations</Keyword><Keyword MajorTopicYN="N">nasal drug</Keyword><Keyword MajorTopicYN="N">respiratory virus</Keyword></KeywordList><CoiStatement>B.Y. and X. J. are associated with the manufacturer that supplies EC16m to Camellix, LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38931912</ArticleId><ArticleId IdType="pmc">PMC11206978</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16060791</ArticleId><ArticleId IdType="pii">pharmaceutics16060791</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hastie C.E., Lowe D.J., Mcauley A., Mills N.L., Winter A.J., Black C., Scott J.T., O&#x2019;Donnell C.A., Blane D.N., Browne S., et al. True prevalence of long-COVID in a nationwide, population cohort study. Nat. Commun. 2023;14:7892. doi: 10.1038/s41467-023-43661-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43661-w</ArticleId><ArticleId IdType="pmc">PMC10689486</ArticleId><ArticleId IdType="pubmed">38036541</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonel J.W., Ciurleo G.C.V., Formiga A.M., Vasconcelos T.d.M.F., de Andrade M.H., Feitosa W.L.Q., Sobreira-Neto A.A., Portugal C.G., Morais L.M., Marinho S.C., et al. Long COVID: Neurological manifestations&#x2014;An updated narrative review. Dement. Neuropsychol. 2024;18:e20230076. doi: 10.1590/1980-5764-dn-2023-0076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1980-5764-dn-2023-0076</ArticleId><ArticleId IdType="pmc">PMC10901563</ArticleId><ArticleId IdType="pubmed">38425701</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou M.-I., Palaiodimou L., Bakola E., Smyrnis N., Papadopoulou M., Paraskevas G.P., Rizos E., Boutati E., Grigoriadis N., Krogias C., et al. Neurological manifestations of long-COVID syndrome: A narrative review. Ther. Adv. Chronic Dis. 2022;13:20406223221076890. doi: 10.1177/20406223221076890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221076890</ArticleId><ArticleId IdType="pmc">PMC8859684</ArticleId><ArticleId IdType="pubmed">35198136</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh J.S., Ericson J.E., Ssentongo P., et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng A., Shah M., Ahmad S.A., Premraj L., Wildi K., Bassi G.L., Pardo C.A., Choi A., Cho S.-M. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12:816. doi: 10.3390/cells12050816.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050816</ArticleId><ArticleId IdType="pmc">PMC10001044</ArticleId><ArticleId IdType="pubmed">36899952</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelalim A.A., Mohamady A.A., Elsayed R.A., Elawady M.A., Ghallab A.F. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial. Am. J. Otolaryngol. 2021;42:102884. doi: 10.1016/j.amjoto.2020.102884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2020.102884</ArticleId><ArticleId IdType="pmc">PMC7836546</ArticleId><ArticleId IdType="pubmed">33429174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S., Lee J.J., Perrin A., Khan A., Smith H.J., Farrell N., Kallogjeri D., Piccirillo J.F. Efficacy and Safety of Saline Nasal Irrigation Plus Theophylline for Treatment of COVID-19-Related Olfactory Dysfunction: The SCENT2 Phase 2 Randomized Clinical Trial. JAMA Otolaryngol. Head. Neck Surg. 2022;148:830&#x2013;837. doi: 10.1001/jamaoto.2022.1573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.1573</ArticleId><ArticleId IdType="pmc">PMC9264240</ArticleId><ArticleId IdType="pubmed">35797024</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao K.T., Cobos-Uribe C., Knight N., Jonnalagadda R., Robinette C., Jaspers I., Rebuli M.E. SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies. J. Allergy Clin. Immunol. Glob. 2023;2:100129. doi: 10.1016/j.jacig.2023.100129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacig.2023.100129</ArticleId><ArticleId IdType="pmc">PMC10290737</ArticleId><ArticleId IdType="pubmed">37781659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleier B.S., Ramanathan M., Jr., Lane A.P. COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission. Otolaryngol. Head. Neck Surg. 2021;164:305&#x2013;307. doi: 10.1177/0194599820982633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820982633</ArticleId><ArticleId IdType="pubmed">33320052</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafloo R., Majidi J., Asghari A., Aleemardani M., Kamrava S.K., Simorgh S., Seifalian A., Bagher Z., Seifalian A.M. Mechanism of Anosmia Caused by Symptoms of COVID-19 and Emerging Treatments. ACS Chem. Neurosci. 2021;12:3795&#x2013;3805. doi: 10.1021/acschemneuro.1c00477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00477</ArticleId><ArticleId IdType="pubmed">34609841</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank N., Dickinson D., Garcia W., Xiao L., Xayaraj A., Lee L.H., Chu T., Kumar M., Stone S., Liu Y., et al. Evaluation of Aqueous Nanoformulations of Epigallocatechin-3-Gallate-Palmitate (EC16) Against Human Coronavirus as a Potential Intervention Drug. Biomed. J. Sci. Tech. Res. 2023;50:2023</Citation></Reference><Reference><Citation>Frank N., Dickinson D., Garcia W., Liu Y., Yu H., Cai J., Patel S., Yao B., Jiang X., Hsu S. Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID. Viruses. 2024;16:196. doi: 10.3390/v16020196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020196</ArticleId><ArticleId IdType="pmc">PMC10891529</ArticleId><ArticleId IdType="pubmed">38399972</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinda B., Dinda S., Dinda M. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases. Phytomed. Plus. 2023;3:100402. doi: 10.1016/j.phyplu.2022.100402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phyplu.2022.100402</ArticleId><ArticleId IdType="pmc">PMC9800022</ArticleId><ArticleId IdType="pubmed">36597465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu S. Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections. Inflamm. Allergy Drug Targets. 2015;14:13&#x2013;18. doi: 10.2174/1871528114666151022150122.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871528114666151022150122</ArticleId><ArticleId IdType="pubmed">26490660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst B.L., Dickinson D., Hsu S. Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells: (A Short Communication) Microbiol. Infect. Dis. 2021;5:1116. doi: 10.33425/2639-9458.1116.</Citation><ArticleIdList><ArticleId IdType="doi">10.33425/2639-9458.1116</ArticleId><ArticleId IdType="pmc">PMC8919953</ArticleId><ArticleId IdType="pubmed">35291211</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Kang Z., Yan W. Synthesis, Stability, and Antidiabetic Activity Evaluation of (&#x2212;)-Epigallo-catechin Gallate (EGCG) Palmitate Derived from Natural Tea Polyphenols. Molecules. 2021;26:393. doi: 10.3390/molecules26020393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26020393</ArticleId><ArticleId IdType="pmc">PMC7828495</ArticleId><ArticleId IdType="pubmed">33451050</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P., Dickinson D., Hsu S. Lipid-soluble Green Tea Polyphenols: Stabilized for Effective Formulation. In: McKinley H., Jamieson M., editors. Handbook of Green Tea and Health Research. Nova Science Publishers, Inc.; New York, NY, USA: 2009. pp. 45&#x2013;61.</Citation></Reference><Reference><Citation>Hsu S., Dickinson D. Green tea and skin protection: Mechanism of action and practical applications. Househ. Pers. Care Today. 2009;2:33&#x2013;36.</Citation></Reference><Reference><Citation>Hsu S., Dickinson D., Borke J., Walsh D.S., Wood J., Qin H., Winger J., Pearl H., Schuster G., Bollag W.B. Green tea polyphenol induces caspase 14 in epidermal keratinocytes via MAPK pathways and reduces psoriasiform lesions in the flaky skin mouse model. Exp. Dermatol. 2007;16:678&#x2013;684. doi: 10.1111/j.1600-0625.2007.00585.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0625.2007.00585.x</ArticleId><ArticleId IdType="pubmed">17620095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie K., Kodani I., Dickinson D.P., Ogbureke K.U.E., Camba A.M., Wu M., Looney S., Chu T.-C., Qin H., Bisch F., et al. Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren&#x2019;s syndrome, an autoimmune disease. Life Sci. 2008;83:581&#x2013;588. doi: 10.1016/j.lfs.2008.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2008.08.011</ArticleId><ArticleId IdType="pmc">PMC2701648</ArticleId><ArticleId IdType="pubmed">18809413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu S.D., Dickinson D.P., Qin H., Borke J., Ogbureke K.U.E., Winger J.N., Camba A.M., Bollag W.B., St&#xf6;ppler H.J., Sharawy M.M., et al. Green tea polyphenols reduce autoimmune symptoms in a murine model for human Sjogren&#x2019;s syndrome and protect human salivary acinar cells from TNF-alpha-induced cytotoxicity. Autoimmunity. 2007;40:138&#x2013;147. doi: 10.1080/08916930601167343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930601167343</ArticleId><ArticleId IdType="pubmed">17364504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson D., DeRossi S., Yu H., Thomas C., Kragor C., Paquin B., Hahn E., Ohno S., Yamamoto T., Hsu S. Epigallocatechin-3-gallate modulates antioxidant defense enzyme expression in murine submandibular and pancreatic exocrine gland cells and human HSG cells. Autoimmunity. 2014;47:177&#x2013;184. doi: 10.3109/08916934.2013.879470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2013.879470</ArticleId><ArticleId IdType="pmc">PMC4301570</ArticleId><ArticleId IdType="pubmed">24444391</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson D., Yu H., Ohno S., Thomas C., DeRossi S., Ma Y.-H., Yates N., Hahn E., Bisch F., Yamamoto T., et al. Epigallocatechin-3-gallate prevents autoimmune-associated down- regulation of p21 in salivary gland cells through a p53-independent pathway. Inflamm. Allergy-Drug Targets. 2014;13:15&#x2013;24. doi: 10.2174/1871528112666131211102500.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871528112666131211102500</ArticleId><ArticleId IdType="pmc">PMC4351656</ArticleId><ArticleId IdType="pubmed">24329914</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre R., de Sola S., Farre M., Xicota L., Cuenca-Royo A., Rodriguez J., Leon A., Langohr K., Gomis-Gonzalez M., Hernandez G., et al. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. Clin. Nutr. 2020;39:378&#x2013;387. doi: 10.1016/j.clnu.2019.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2019.02.028</ArticleId><ArticleId IdType="pubmed">30962103</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N.A., Mandal A.K., Khan Z.A. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG) Nutr. J. 2016;15:60. doi: 10.1186/s12937-016-0179-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0179-4</ArticleId><ArticleId IdType="pmc">PMC4897892</ArticleId><ArticleId IdType="pubmed">27268025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano A., Ettcheto M., Espina M., Auladell C., Calpena A.C., Folch J., Barenys M., S&#xe1;nchez-L&#xf3;pez E., Camins A., Garc&#xed;a M.L. Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. Nanomed. Nanotechnol. Biol. Med. 2018;14:1073&#x2013;1085. doi: 10.1016/j.nano.2018.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2018.01.019</ArticleId><ArticleId IdType="pubmed">29454994</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z.Y., Li X.M., Liang J.P., Xiang L.P., Wang K.R., Shi Y.L., Yang R., Shi M., Ye J.H., Lu J.L., et al. Bioavailability of Tea Catechins and Its Improvement. Molecules. 2018;23:2346. doi: 10.3390/molecules23092346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23092346</ArticleId><ArticleId IdType="pmc">PMC6225109</ArticleId><ArticleId IdType="pubmed">30217074</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.S., Chen L., Lee M.J., Balentine D., Kuo M.C., Schantz S.P. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomark. Prev. 1998;7:351&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J., Dickinson D., Sampath L., Hsu S. Effects of Epigallocatechin-3-Gallate-Palmitate (EC16) on In Vitro Norovirus Infection. Microbiol. Infect. Dis. 2021;5:1&#x2013;7. doi: 10.33425/2639-9458.1139.</Citation><ArticleIdList><ArticleId IdType="doi">10.33425/2639-9458.1139</ArticleId><ArticleId IdType="pmc">PMC8959116</ArticleId><ArticleId IdType="pubmed">35350749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y., Chen P., Ling T., Wang Y., Dong R., Zhang C., Zhang L., Han M., Wang D., Wan X., et al. Certain (-)-epigallocatechin-3-gallate (EGCG) auto-oxidation products (EAOPs) retain the cytotoxic activities of EGCG. Food Chem. 2016;204:218&#x2013;226. doi: 10.1016/j.foodchem.2016.02.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2016.02.134</ArticleId><ArticleId IdType="pubmed">26988496</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira A., Adams S.D., Lee L.H., Murray S.R., Hsu S.D., Hammond J.R., Dickinson D., Chen P., Chu T.C. Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol palmitoyl-epigallocatechin gallate. Food Chem. Toxicol. 2013;52:207&#x2013;215. doi: 10.1016/j.fct.2012.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2012.11.006</ArticleId><ArticleId IdType="pmc">PMC3703635</ArticleId><ArticleId IdType="pubmed">23182741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S., Miyake S., Kobe T., Nakaya T., Fuller S.D., Kato N., Kaihatsu K. Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: Effect of alkyl chain length. Bioorg Med. Chem. Lett. 2008;18:4249&#x2013;4252. doi: 10.1016/j.bmcl.2008.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.02.020</ArticleId><ArticleId IdType="pubmed">18547804</ArticleId></ArticleIdList></Reference><Reference><Citation>Barhoum A., Garc&#xed;a-Betancourt M.L., Jeevanandam J., Hussien E.A., Mekkawy S.A., Mostafa M., Omran M.M., Abdalla M.S., Bechelany M. Review on Natural, Incidental, Bioinspired, and Engineered Nanomaterials: History, Definitions, Classifications, Synthesis, Properties, Market, Toxicities, Risks, and Regulations. Nanomaterials. 2022;12:177. doi: 10.3390/nano12020177.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano12020177</ArticleId><ArticleId IdType="pmc">PMC8780156</ArticleId><ArticleId IdType="pubmed">35055196</ArticleId></ArticleIdList></Reference><Reference><Citation>Farabegoli F., Granja A., Magalh&#xe3;es J., Purgato S., Voltattorni M., Pinheiro M. Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines. ACS Omega. 2022;7:41872&#x2013;41881. doi: 10.1021/acsomega.2c01829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.2c01829</ArticleId><ArticleId IdType="pmc">PMC9685782</ArticleId><ArticleId IdType="pubmed">36440117</ArticleId></ArticleIdList></Reference><Reference><Citation>Farabegoli F., Pinheiro M. Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy. Front. Pharmacol. 2022;13:809706. doi: 10.3389/fphar.2022.809706.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.809706</ArticleId><ArticleId IdType="pmc">PMC9046542</ArticleId><ArticleId IdType="pubmed">35496283</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.-H., Hsieh C.-H., Tsai S.-Y., Wang C.-Y., Wang C.-C. Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Sci. Rep. 2020;10:5163. doi: 10.1038/s41598-020-62136-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62136-2</ArticleId><ArticleId IdType="pmc">PMC7083948</ArticleId><ArticleId IdType="pubmed">32198390</ArticleId></ArticleIdList></Reference><Reference><Citation>He A., Guan X., Song H., Li S., Huang K. Encapsulation of (&#x2212;)-epigallocatechin-gallate (EGCG) in hordein nanoparticles. Food Biosci. 2020;37:100727. doi: 10.1016/j.fbio.2020.100727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fbio.2020.100727</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H., He A., Guan X., Chen Z., Bao Y., Huang K. Fabrication of chitosan-coated epigallocatechin-3-gallate (EGCG)-hordein nanoparticles and their transcellular permeability in Caco-2/HT29 cocultures. Int. J. Biol. Macromol. 2022;196:144&#x2013;150. doi: 10.1016/j.ijbiomac.2021.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2021.12.024</ArticleId><ArticleId IdType="pubmed">34914913</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Jiang Z., Ma L., Huang Q. Advances in Nanodelivery of Green Tea Catechins to Enhance the Anticancer Activity. Molecules. 2021;26:3301. doi: 10.3390/molecules26113301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26113301</ArticleId><ArticleId IdType="pmc">PMC8198522</ArticleId><ArticleId IdType="pubmed">34072700</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzyzowska M., Janicka M., Chodkowski M., Patrycy M., Obuch-Woszczaty&#x144;ska O., Tomaszewska E., Ranoszek-Soliwoda K., Celichowski G., Grobelny J. Epigallocatechin Gallate-Modified Silver Nanoparticles Show Antiviral Activity against Herpes Simplex Type 1 and 2. Viruses. 2023;15:2024. doi: 10.3390/v15102024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15102024</ArticleId><ArticleId IdType="pmc">PMC10611064</ArticleId><ArticleId IdType="pubmed">37896801</ArticleId></ArticleIdList></Reference><Reference><Citation>Meesaragandla B., Hayet S., Fine T., Janke U., Chai L., Delcea M. Inhibitory Effect of Epigallocatechin Gallate-Silver Nanoparticles and Their Lysozyme Bioconjugates on Biofilm Formation and Cytotoxicity. ACS Appl. Bio Mater. 2022;5:4213&#x2013;4221. doi: 10.1021/acsabm.2c00409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsabm.2c00409</ArticleId><ArticleId IdType="pmc">PMC9490750</ArticleId><ArticleId IdType="pubmed">35977081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakakura Y., Ukai K., Majima Y., Murai S., Harada T., Miyoshi Y. Nasal mucociliary clearance under various conditions. Acta Otolaryngol. 1983;96:167&#x2013;173. doi: 10.3109/00016488309132888.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00016488309132888</ArticleId><ArticleId IdType="pubmed">6613546</ArticleId></ArticleIdList></Reference><Reference><Citation>Helwa I., Cai J., Drewry M.D., Zimmerman A., Dinkins M.B., Khaled M.L., Seremwe M., Dismuke W.M., Bieberich E., Stamer W.D., et al. A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents. PLoS ONE. 2017;12:e0170628. doi: 10.1371/journal.pone.0170628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0170628</ArticleId><ArticleId IdType="pmc">PMC5256994</ArticleId><ArticleId IdType="pubmed">28114422</ArticleId></ArticleIdList></Reference><Reference><Citation>Muench H.R. A simple method of estimating 50 per cent end points. Am. J. Hyg. 1938;27:493&#x2013;497.</Citation></Reference><Reference><Citation>US FDA GRAS NOTICE 772, U.G.N.  GRAS Notice for Oil-Soluble Green Tea Extract (Green Tea Catechin Palmitate)  [(accessed on 28 April 2024)];2018  Available online:  https://www.fda.gov/media/126906/download.</Citation></Reference><Reference><Citation>Rabago D., Zgierska A. Saline nasal irrigation for upper respiratory conditions. Am. Fam. Physician. 2009;80:1117&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778074</ArticleId><ArticleId IdType="pubmed">19904896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.I., Lee C. Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19. Viruses. 2023;15:578. doi: 10.3390/v15020578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020578</ArticleId><ArticleId IdType="pmc">PMC9965565</ArticleId><ArticleId IdType="pubmed">36851792</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo G.D., Lazarini F., Levallois S., Hautefort C., Michel V., Larrous F., Verillaud B., Aparicio C., Wagner S., Gheusi G., et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci. Transl. Med. 2021;13:abf8396. doi: 10.1126/scitranslmed.abf8396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8396</ArticleId><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>